

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)


Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

1645

BIOTECHNOLOGY  
SYSTEMS  
BRANCH



**RAW SEQUENCE LISTING**  
**ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/612,925B  
Source: 1600  
Date Processed by STIC: 7/24/2002

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

OCT 21 2002

RECEIVED

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER  
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND  
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebs/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

# Raw Sequence Listing Error Summary

## ERROR DETECTED

## SUGGESTED CORRECTION

SERIAL NUMBER: 09/612925B

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1      Wrapped Nucleics  
    Wrapped Aminos      The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2      Invalid Line Length      The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3      Misaligned Amino  
    Numbering      The numbering under each 5<sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4      Non-ASCII      The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5      Variable Length      Sequence(s)      contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6      PatentIn 2.0  
    "bug"      A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s)     . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7      Skipped Sequences  
    (OLD RULES)      Sequence(s)      missing. If intentional, please insert the following lines for each skipped sequence:  
    (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
    (i)      SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  
    (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
    This sequence is intentionally skipped  
  
    Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8      Skipped Sequences  
    (NEW RULES)      Sequence(s)      missing. If intentional, please insert the following lines for each skipped sequence.  
    <210> sequence id number  
    <400> sequence id number  
    000
- 9      Use of n's or Xaa's  
    (NEW RULES)      Use of n's and/or Xaa's have been detected in the Sequence Listing.  
    Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  
    In <220> to <223> section, please explain location of n or Xaa; and which residue n or Xaa represents.
- 10 ✓ Invalid <213>  
    Response      Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11      Use of <220>      Sequence(s)      missing the <220> "Feature" and associated numeric identifiers and responses.  
    Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  
    (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12      PatentIn 2.0  
    "bug"      Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13      Misuse of n      n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.



1645

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/612,925B

DATE: 07/24/2002  
TIME: 14:24:11

Input Set : A:\sequence listing.txt  
Output Set: N:\CRF3\07242002\I612925B.raw

P.4

Does Not Comply  
Corrected Diskette Needed

3 <110> APPLICANT: Cano, Carlos Antonio Durante  
4 Nieto, Enrique Gerardo Guillen  
5 Acosta, Anabel Alvarez  
6 Munoz, Luis Emilio Carpio  
7 Vazquez, Diogenes Quintana  
8 Rodriguez, Carmen Elena Gomez Rodriguez  
9 Rodriguez, Recardo de la Caridad Siva  
10 Galvez, Consuelo Nazabal  
11 Angulo, Maria de Jesus Leal  
12 Dunn, Alejandro Miguel Martin  
14 <120> TITLE OF INVENTION: System for the Expression of Heterologous Antigens as Fusion Proteins  
16 <130> FILE REFERENCE: LEXSA P-13DIV2  
18 <140> CURRENT APPLICATION NUMBER: 09/612,925B  
19 <141> CURRENT FILING DATE: 2000-07-10  
21 <150> PRIOR APPLICATION NUMBER: 08/930,917  
22 <151> PRIOR FILING DATE: 1997-09-16  
24 <150> PRIOR APPLICATION NUMBER: CU97/00001  
25 <151> PRIOR FILING DATE: 1997-01-17  
27 <160> NUMBER OF SEQ ID NOS: 21  
29 <170> SOFTWARE: PatentIn version 3.1  
31 <210> SEQ ID NO: 1  
32 <211> LENGTH: 47  
33 <212> TYPE: PRT  
34 <213> ORGANISM: Neisseria meningitidis  
36 <400> SEQUENCE: 1  
38 Met Leu Asp Lys Arg Met Ala Leu Val Glu Leu Lys Val Pro Asp Ile  
39 1 5 10 15  
42 Gly Gly His Glu Asn Val Asp Ile Ile Ala Val Glu Val Asn Val Gly  
43 20 25 30  
46 Asp Thr Ile Ala Val Asp Asp Thr Leu Ile Thr Leu Glu Thr Asp  
47 35 40 45  
50 <210> SEQ ID NO: 2  
51 <211> LENGTH: 18  
52 <212> TYPE: PRT  
53 <213> ORGANISM: Neisseria meningitidis  
55 <400> SEQUENCE: 2  
57 Thr Thr Cys Cys Ala Thr Gly Gly Thr Ala Gly Ala Thr Ala Ala Ala  
58 1 5 10 15  
61 Ala Gly  
65 <210> SEQ ID NO: 3  
66 <211> LENGTH: 18  
67 <212> TYPE: PRT  
68 <213> ORGANISM: Neisseria meningitidis

RECEIVED

OCT 21 2002

TECH CENTER 1600/2900

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/612,925B

DATE: 07/24/2002  
TIME: 14:24:11

Input Set : A:\sequence listing.txt  
Output Set: N:\CRF3\07242002\I612925B.raw

70 <400> SEQUENCE: 3  
72 Thr Thr Thr Cys Thr Ala Gly Ala Thr Cys Cys Ala Ala Ala Gly Thr  
73 1 5 10 15  
76 Ala Ala  
80 <210> SEQ ID NO: 4  
81 <211> LENGTH: 26  
82 <212> TYPE: PRT  
83 <213> ORGANISM: Neisseria meningitidis  
85 <400> SEQUENCE: 4  
87 Gly Gly Cys Gly Gly Thr Thr Cys Thr Gly Cys Cys Gly Ala Thr Thr  
88 1 5 10 15  
91 Ala Ala Gly Gly Ala Thr Cys Cys Gly Ala  
92 20 25  
95 <210> SEQ ID NO: 5  
96 <211> LENGTH: 146  
97 <212> TYPE: PRT  
98 <213> ORGANISM: Neisseria meningitidis  
100 <400> SEQUENCE: 5  
102 Thr Thr Cys Cys Ala Thr Gly Gly Thr Ala Gly Ala Thr Ala Ala Ala  
103 1 5 10 15  
106 Ala Gly Ala Ala Thr Gly Gly Cys Thr Thr Thr Ala Gly Thr Thr Gly  
107 20 25 30  
110 Ala Ala Thr Thr Gly Ala Ala Ala Gly Thr Gly Cys Cys Cys Gly Ala  
111 35 40 45  
114 Cys Ala Thr Thr Gly Gly Cys Gly Gly Ala Cys Ala Cys Gly Ala Ala  
115 50 55 60  
118 Ala Ala Thr Gly Thr Ala Gly Ala Thr Ala Thr Ala Thr Cys Gly  
119 65 70 75 80  
122 Cys Gly Gly Thr Thr Gly Ala Ala Gly Thr Ala Ala Ala Cys Gly Thr  
123 85 90 95  
126 Gly Gly Gly Cys Gly Ala Cys Ala Cys Thr Ala Thr Thr Gly Cys Thr  
127 100 105 110  
130 Gly Thr Gly Gly Ala Cys Gly Ala Thr Ala Cys Cys Cys Thr Gly Ala  
131 115 120 125  
134 Thr Thr Ala Cys Thr Thr Thr Gly Gly Ala Thr Cys Thr Ala Gly Ala  
135 130 135 140  
138 Ala Ala  
139 145  
142 <210> SEQ ID NO: 6  
143 <211> LENGTH: 47  
144 <212> TYPE: PRT  
145 <213> ORGANISM: Neisseria meningitidis  
147 <400> SEQUENCE: 6  
149 Met Val Asp Lys Arg Met Ala Leu Val Glu Leu Lys Val Pro Asp Ile  
150 1 5 10 15  
153 Gly Gly His Glu Asn Val Asp Ile Ile Ala Val Glu Val Asn Val Gly  
154 20 25 30  
157 Asp Thr Ile Ala Val Asp Asp Thr Leu Ile Thr Leu Asp Leu Glu  
158 35 40 45

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/612,925B

DATE: 07/24/2002  
TIME: 14:24:11

Input Set : A:\sequence listing.txt  
Output Set: N:\CRF3\07242002\I612925B.raw

```
161 <210> SEQ ID NO: 7
162 <211> LENGTH: 16
163 <212> TYPE: PRT
164 <213> ORGANISM: Neisseria meningitidis
166 <400> SEQUENCE: 7
168 Cys Thr Ala Gly Ala Thr Thr Thr Gly Ala Thr Ala Thr Cys Ala Gly
169 1 5 10 15
172 <210> SEQ ID NO: 8
173 <211> LENGTH: 16
174 <212> TYPE: PRT
175 <213> ORGANISM: Neisseria meningitidis
177 <400> SEQUENCE: 8
179 Gly Ala Thr Cys Cys Thr Gly Ala Thr Ala Thr Cys Ala Ala Ala Thr
180 1 5 10 15
183 <210> SEQ ID NO: 9
184 <211> LENGTH: 15
185 <212> TYPE: PRT
186 <213> ORGANISM: Human immunodeficiency virus type 1
188 <400> SEQUENCE: 9
190 Ser Arg Gly Ile Arg Ile Gly Pro Gly Arg Ala Ile Leu Ala Thr
191 1 5 10 15
194 <210> SEQ ID NO: 10
195 <211> LENGTH: 15
196 <212> TYPE: PRT
197 <213> ORGANISM: Human immunodeficiency virus type 1
199 <400> SEQUENCE: 10
201 Arg Gln Ser Thr Pro Ile Gly Leu Gly Gln Ala Leu Tyr Thr Thr
202 1 5 10 15
205 <210> SEQ ID NO: 11
206 <211> LENGTH: 15
207 <212> TYPE: PRT
208 <213> ORGANISM: Human immunodeficiency virus type 1
210 <400> SEQUENCE: 11
212 Arg Lys Ser Ile Thr Lys Gly Pro Gly Arg Val Ile Tyr Ala Thr
213 1 5 10 15
216 <210> SEQ ID NO: 12
217 <211> LENGTH: 15
218 <212> TYPE: PRT
219 <213> ORGANISM: Human immunodeficiency virus type 1
221 <400> SEQUENCE: 12
223 Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr
224 1 5 10 15
227 <210> SEQ ID NO: 13
228 <211> LENGTH: 15
229 <212> TYPE: PRT
230 <213> ORGANISM: Human immunodeficiency virus type 1
232 <400> SEQUENCE: 13
234 Arg Lys Arg Ile Thr Met Gly Pro Gly Arg Val Tyr Tyr Thr Thr
235 1 5 10 15
```

## RAW SEQUENCE LISTING

DATE: 07/24/2002

PATENT APPLICATION: US/09/612,925B

TIME: 14:24:11

Input Set : A:\sequence listing.txt

Output Set: N:\CRF3\07242002\I612925B.raw

238 <210> SEQ ID NO: 14  
 239 <211> LENGTH: 15  
 240 <212> TYPE: PRT  
 241 <213> ORGANISM: Human immunodeficiency virus type 1  
 243 <400> SEQUENCE: 14  
 245 Ser Ile Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile  
 246 1 5 10 15  
 249 <210> SEQ ID NO: 15  
 250 <211> LENGTH: 15  
 251 <212> TYPE: PRT  
 252 <213> ORGANISM: Human immunodeficiency virus type 1  
 254 <400> SEQUENCE: 15  
 256 Thr Ser Ile Thr Ile Gly Pro Gly Gln Val Phe Tyr Arg Thr Gly  
 257 1 5 10 15  
 260 <210> SEQ ID NO: 16  
 261 <211> LENGTH: 15  
 262 <212> TYPE: PRT  
 263 <213> ORGANISM: Human immunodeficiency virus type 1  
 265 <400> SEQUENCE: 16  
 267 Arg Gln Arg Thr Ser Ile Gly Gln Gly Gln Ala Leu Tyr Thr Thr  
 268 1 5 10 15  
 271 <210> SEQ ID NO: 17  
 272 <211> LENGTH: 5  
 273 <212> TYPE: PRT  
 274 <213> ORGANISM: unidentified  
 276 <400> SEQUENCE: 17  
 278 Ala Gly Gly Gly Ala  
 279 1 5  
 282 <210> SEQ ID NO: 18  
 283 <211> LENGTH: 141  
 284 <212> TYPE: PRT  
 285 <213> ORGANISM: Human immunodeficiency virus type 1  
 287 <400> SEQUENCE: 18  
 289 Cys Ala Pro Thr Ser Ser Ser Thr Ala Gln Thr Gln Leu Gln Leu Glu  
 290 1 5 10 15  
 293 His Leu Leu Leu Asp Leu Gln Ile Phe Leu Ser Arg Gly Ile Arg Ile  
 294 20 25 30  
 297 Gly Pro Gly Arg Ala Ile Leu Ala Thr Ala Gly Gly Gly Ala Arg Gln  
 298 35 40 45  
 301 Ser Thr Pro Ile Gly Leu Gly Gly Ala Leu Tyr Thr Thr Ala Gly Gly  
 302 50 55 60  
 305 Gly Ala Arg Lys Ser Ile Thr Lys Gly Pro Gly Arg Val Ile Tyr Ala  
 306 65 70 75 80  
 309 Thr Ala Gly Gly Gly Ala Arg Lys Arg Ile His Ile Gly Pro Gly Arg  
 310 85 90 95  
 313 Ala Phe Tyr Thr Thr Ala Gly Gly Gly Ala Arg Lys Arg Ile Thr Met  
 314 100 105 110  
 317 Gly Pro Gly Arg Val Tyr Tyr Thr Thr Ala Gly Gly Gly Ala Ser Ile  
 318 115 120 125

*inhib response - see item 10 on Eval*

*Summary*

*Sheet*

## RAW SEQUENCE LISTING

DATE: 07/24/2002

PATENT APPLICATION: US/09/612,925B

TIME: 14:24:11

Input Set : A:\sequence listing.txt

Output Set: N:\CRF3\07242002\I612925B.raw

```

321 Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile
322     130                      135                      140
325 <210> SEQ ID NO: 19
326 <211> LENGTH: 162
327 <212> TYPE: PRT
328 <213> ORGANISM: Human immunodeficiency virus type 1
330 <400> SEQUENCE: 19
332 Met Val Asp Lys Arg Met Ala Leu Val Glu Leu Lys Val Pro Asp Ile
333 1           5           10           15
336 Gly Gly His Glu Asn Val Asp Ile Ile Ala Val Glu Val Asn Val Gly
337           20           25           30
340 Asp Thr Ile Ala Val Asp Asp Thr Leu Ile Thr Leu Asp Leu Asp Ser
341           35           40           45
344 Arg Gly Ile Arg Ile Gly Pro Gly Arg Ala Ile Leu Ala Thr Ala Gly
345           50           55           60
348 Gly Gly Ala Arg Gln Ser Thr Pro Ile Gly Leu Gly Gly Ala Leu Tyr
349 65           70           75           80
352 Thr Thr Ala Gly Gly Gly Ala Arg Lys Ser Ile Thr Lys Gly Pro Gly
353           85           90           95
356 Arg Val Ile Tyr Ala Thr Ala Gly Gly Gly Ala Arg Lys Arg Ile His
357           100          105          110
360 Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Ala Gly Gly Gly Ala Arg
361           115          120          125
364 Lys Arg Ile Thr Met Gly Pro Gly Arg Val Tyr Tyr Thr Thr Ala Gly
365           130          135          140
368 Gly Gly Ala Ser Ile Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val
369 145          150          155          160
372 Thr Ile
376 <210> SEQ ID NO: 20
377 <211> LENGTH: 202
378 <212> TYPE: PRT
379 <213> ORGANISM: Human immunodeficiency virus type 1
381 <400> SEQUENCE: 20
383 Met Val Asp Lys Arg Met Ala Leu Val Glu Leu Lys Val Pro Asp Ile
384 1           5           10           15
387 Gly Gly His Glu Asn Val Asp Ile Ile Ala Val Glu Val Asn Val Gly
388           20           25           30
391 Asp Thr Ile Ala Val Asp Asp Thr Leu Ile Thr Leu Asp Leu Asp Ser
392           35           40           45
395 Arg Gly Ile Arg Ile Gly Pro Gly Arg Ala Ile Leu Ala Thr Ala Gly
396           50           55           60
399 Gly Gly Ala Arg Gln Ser Thr Pro Ile Gly Leu Gly Gln Ala Leu Tyr
400 65           70           75           80
403 Thr Thr Ala Gly Gly Gly Ala Arg Lys Ser Ile Thr Lys Gly Pro Gly
404           85           90           95
407 Arg Val Ile Tyr Ala Thr Ala Gly Gly Gly Ala Arg Lys Arg Ile His
408           100          105          110
411 Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Ala Gly Gly Gly Ala Arg
412           115          120          125

```



VERIFICATION SUMMARY

PATENT APPLICATION: US/09/612,925B

DATE: 07/24/2002

TIME: 14:24:12

Input Set : A\*\sequence listing.txt

Output Set: N:\CRF3\07242002\I612925B.raw